Koers LIDDS AB (publ) Nasdaq Stockholm
Aandelen
SE0001958612
Biotechnologie & Medisch Onderzoek
Omzet 2021 | 3,55 mln. 329K 305K | Omzet 2022 | 1,89 mln. 175K 162K | Marktkapitalisatie | 58,92 mln. 5,45 mln. 5,06 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -37 mln. -3,42 mln. -3,18 mln. | Nettowinst (verlies) 2022 | -36 mln. -3,33 mln. -3,09 mln. | EV/omzet 2021 | 81,8 x |
Nettoliquiditeiten 2021 | 34 mln. 3,15 mln. 2,92 mln. | Nettoliquiditeiten 2022 | 1,26 mln. 117K 109K | EV/omzet 2022 | 30,5 x |
K/w-verhouding 2021 |
-8,2
x | K/w-verhouding 2022 |
-1,58
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 63,36% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 53 | 01-12-21 | |
Kia Bengtsson
PRN | Corporate Officer/Principal | - | 01-10-22 |
Niklas Axén
PRN | Corporate Officer/Principal | 61 | 01-01-04 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 62 | 09/01 | |
Director/Board Member | 62 | 09/01 | |
David Bejker
BRD | Director/Board Member | 49 | 01-01-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+5,50% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-6,50% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |